Algernon is trailblazing a new treatment option for stroke could it work?
b'
Christopher J. Moreau, CEO of Algernon Pharmaceuticals (CSE: AGN | FRANKFURT: AGW | OTCQB: AGNPF) discusses the company\\u2019s clinical research program for stroke focused on AP-188 (\\u201cDMT\\u201d), a known psychedelic compound that is part of the tryptamine family.
Algernon Pharmaceuticals Inc. is a drug re-purposing company that investigates safe, already approved drugs, and naturally occurring compounds, for new disease applications, moving them efficiently and safely into new human trials, developing new formulations and seeking new regulatory approvals in global markets.